Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Analysis of study funded by Johnson & Johnson (n=805) indicates that this vaccine candidate is safe and immunogenic in both younger and older adults and supports decision to proceed with two phase 3 trials evaluating efficacy of either a single or 2 dose regimen of lower dose,

New England Journal of Medicine